The Experts below are selected from a list of 147351 Experts worldwide ranked by ideXlab platform
Charles P O'brien - One of the best experts on this subject based on the ideXlab platform.
-
Initiating acamprosate within-Detoxification versus post-Detoxification in the treatment of alcohol dependence.
Addictive behaviors, 2009Co-Authors: Kyle M Kampman, Helen M Pettinati, Kevin G Lynch, Hu Xie, Charles Dackis, David W Oslin, Thorne Sparkman, Tiffany Sharkoski, Charles P O'brienAbstract:This trial compared the efficacy of acamprosate, started at the beginning of Detoxification, to acamprosate started at the completion of Detoxification, in the treatment of alcohol dependence. This biphasic clinical trial consisted of a randomized, double-blind, placebo-controlled Detoxification Phase (DP), followed by a 10-week open-label Rehabilitation Phase (RP). Forty alcohol dependent patients were randomly assigned to receive either 1998 mg of acamprosate daily, or matching placebo, during the DP (5-14 days). After completing Detoxification, all patients received open label acamprosate (1998 mg daily) in the RP. Outcome measures during the DP included: treatment retention, alcohol withdrawal, alcohol consumption, and oxazepam used. Outcome measures during the RP included: treatment retention and alcohol consumption. There were no significant outcome differences between acamprosate and placebo-treated patients during the DP. Patients given acamprosate, compared to placebo, during the DP drank more alcohol in the RP. Starting acamprosate at the beginning of Detoxification did not improve DP outcomes. Starting acamprosate after Detoxification was completed was associated with better drinking outcomes during subsequent alcohol rehabilitation treatment.
-
Initiating acamprosate within-Detoxification versus post-Detoxification in the treatment of alcohol dependence
Addictive Behaviors, 2009Co-Authors: Kyle M Kampman, Helen M Pettinati, Kevin G Lynch, Hu Xie, Charles Dackis, David W Oslin, Thorne Sparkman, Tiffany Sharkoski, Charles P O'brienAbstract:Abstract Objectives This trial compared the efficacy of acamprosate, started at the beginning of Detoxification, to acamprosate started at the completion of Detoxification, in the treatment of alcohol dependence. Methods This biphasic clinical trial consisted of a randomized, double-blind, placebo-controlled Detoxification Phase (DP), followed by a 10-week open-label Rehabilitation Phase (RP). Forty alcohol dependent patients were randomly assigned to receive either 1998 mg of acamprosate daily, or matching placebo, during the DP (5–14 days). After completing Detoxification, all patients received open label acamprosate (1998 mg daily) in the RP. Outcome measures during the DP included: treatment retention, alcohol withdrawal, alcohol consumption, and oxazepam used. Outcome measures during the RP included: treatment retention and alcohol consumption. Results There were no significant outcome differences between acamprosate and placebo-treated patients during the DP. Patients given acamprosate, compared to placebo, during the DP drank more alcohol in the RP. Conclusions Starting acamprosate at the beginning of Detoxification did not improve DP outcomes. Starting acamprosate after Detoxification was completed was associated with better drinking outcomes during subsequent alcohol rehabilitation treatment.
George D. Wendel - One of the best experts on this subject based on the ideXlab platform.
-
Opioid Detoxification in pregnancy.
Obstetrics and gynecology, 1998Co-Authors: Jodi S. Dashe, Gregory L. Jackson, Debora A. Olscher, Elizabeth H. Zane, George D. WendelAbstract:Abstract Objective: Opioid withdrawal has been associated with poor fetal growth, preterm delivery, and fetal death. We sought to evaluate the safety of antepartum opioid Detoxification in selected gravidas. Methods: Between 1990 and 1996, women with singleton gestations who reported opioid use were offered inpatient Detoxification. PreDetoxification sonography was performed to confirm gestational age and to exclude fetuses with growth restriction and oligohydramnios. Women with mild withdrawal symptoms were given clonidine initially, and methadone was substituted if symptoms persisted. Objective signs of withdrawal were treated with methadone from the outset. Antenatal testing was performed once gestations reached 24 weeks. Newborns were observed for signs of neonatal abstinence syndrome and were treated as necessary. Obstetric and neonatal outcome data were collected. Results: Thirty-four gravidas elected to undergo opioid Detoxification at a mean gestational age of 24 weeks. The median maximum dose of methadone was 20 mg per day (range 10–85 mg), and the median time to Detoxification was 12 days (range 3–39 days). Overall, 20 women (59%) successfully underwent Detoxification and did not relapse, ten (29%) resumed antenatal opioid use, and four (12%) did not complete Detoxification and opted for methadone maintenance. There was no evidence of fetal distress during Detoxification, no fetal death, and no delivery before 36 weeks. Fifteen percent of neonates were treated for narcotic withdrawal. Conclusion: In selected patients, opioid Detoxification can be accomplished safely during pregnancy.
Kyle M Kampman - One of the best experts on this subject based on the ideXlab platform.
-
Initiating acamprosate within-Detoxification versus post-Detoxification in the treatment of alcohol dependence.
Addictive behaviors, 2009Co-Authors: Kyle M Kampman, Helen M Pettinati, Kevin G Lynch, Hu Xie, Charles Dackis, David W Oslin, Thorne Sparkman, Tiffany Sharkoski, Charles P O'brienAbstract:This trial compared the efficacy of acamprosate, started at the beginning of Detoxification, to acamprosate started at the completion of Detoxification, in the treatment of alcohol dependence. This biphasic clinical trial consisted of a randomized, double-blind, placebo-controlled Detoxification Phase (DP), followed by a 10-week open-label Rehabilitation Phase (RP). Forty alcohol dependent patients were randomly assigned to receive either 1998 mg of acamprosate daily, or matching placebo, during the DP (5-14 days). After completing Detoxification, all patients received open label acamprosate (1998 mg daily) in the RP. Outcome measures during the DP included: treatment retention, alcohol withdrawal, alcohol consumption, and oxazepam used. Outcome measures during the RP included: treatment retention and alcohol consumption. There were no significant outcome differences between acamprosate and placebo-treated patients during the DP. Patients given acamprosate, compared to placebo, during the DP drank more alcohol in the RP. Starting acamprosate at the beginning of Detoxification did not improve DP outcomes. Starting acamprosate after Detoxification was completed was associated with better drinking outcomes during subsequent alcohol rehabilitation treatment.
-
Initiating acamprosate within-Detoxification versus post-Detoxification in the treatment of alcohol dependence
Addictive Behaviors, 2009Co-Authors: Kyle M Kampman, Helen M Pettinati, Kevin G Lynch, Hu Xie, Charles Dackis, David W Oslin, Thorne Sparkman, Tiffany Sharkoski, Charles P O'brienAbstract:Abstract Objectives This trial compared the efficacy of acamprosate, started at the beginning of Detoxification, to acamprosate started at the completion of Detoxification, in the treatment of alcohol dependence. Methods This biphasic clinical trial consisted of a randomized, double-blind, placebo-controlled Detoxification Phase (DP), followed by a 10-week open-label Rehabilitation Phase (RP). Forty alcohol dependent patients were randomly assigned to receive either 1998 mg of acamprosate daily, or matching placebo, during the DP (5–14 days). After completing Detoxification, all patients received open label acamprosate (1998 mg daily) in the RP. Outcome measures during the DP included: treatment retention, alcohol withdrawal, alcohol consumption, and oxazepam used. Outcome measures during the RP included: treatment retention and alcohol consumption. Results There were no significant outcome differences between acamprosate and placebo-treated patients during the DP. Patients given acamprosate, compared to placebo, during the DP drank more alcohol in the RP. Conclusions Starting acamprosate at the beginning of Detoxification did not improve DP outcomes. Starting acamprosate after Detoxification was completed was associated with better drinking outcomes during subsequent alcohol rehabilitation treatment.
Jodi S. Dashe - One of the best experts on this subject based on the ideXlab platform.
-
Opioid Detoxification in pregnancy.
Obstetrics and gynecology, 1998Co-Authors: Jodi S. Dashe, Gregory L. Jackson, Debora A. Olscher, Elizabeth H. Zane, George D. WendelAbstract:Abstract Objective: Opioid withdrawal has been associated with poor fetal growth, preterm delivery, and fetal death. We sought to evaluate the safety of antepartum opioid Detoxification in selected gravidas. Methods: Between 1990 and 1996, women with singleton gestations who reported opioid use were offered inpatient Detoxification. PreDetoxification sonography was performed to confirm gestational age and to exclude fetuses with growth restriction and oligohydramnios. Women with mild withdrawal symptoms were given clonidine initially, and methadone was substituted if symptoms persisted. Objective signs of withdrawal were treated with methadone from the outset. Antenatal testing was performed once gestations reached 24 weeks. Newborns were observed for signs of neonatal abstinence syndrome and were treated as necessary. Obstetric and neonatal outcome data were collected. Results: Thirty-four gravidas elected to undergo opioid Detoxification at a mean gestational age of 24 weeks. The median maximum dose of methadone was 20 mg per day (range 10–85 mg), and the median time to Detoxification was 12 days (range 3–39 days). Overall, 20 women (59%) successfully underwent Detoxification and did not relapse, ten (29%) resumed antenatal opioid use, and four (12%) did not complete Detoxification and opted for methadone maintenance. There was no evidence of fetal distress during Detoxification, no fetal death, and no delivery before 36 weeks. Fifteen percent of neonates were treated for narcotic withdrawal. Conclusion: In selected patients, opioid Detoxification can be accomplished safely during pregnancy.
Shmuel Atias - One of the best experts on this subject based on the ideXlab platform.
-
Outcomes of Naltrexone Maintenance Following Ultra Rapid Opiate Detoxification Versus Intensive Inpatient Detoxification
The American journal on addictions, 2002Co-Authors: Jonathan Rabinowitz, Hagit Cohen, Shmuel AtiasAbstract:Relapse rates of 30 opiate-addicted social service clients who were given a 9-month course of naltrexone after being rapidly detoxified using naltrexone + clonidine under anesthesia were compared to 33 similar clients detoxified in a 30-day intensive inpatient Detoxification but not given naltrexone. Both groups had the same counseling aftercare. Telephone follow-up of 26 of the intensive inpatient Detoxification clients and 24 of the rapidly detoxified clients found no significant differences (p =. 62) in relapse rates, with 34% of respondents returning to regular opiate use 13.4 ( - 3.8) months after Detoxification. Naltrexone maintenance and counseling following rapid Detoxification may be as effective as intensive inpatient Detoxification and counseling.